article · Benha Journal of Applied Sciences
Background: When contrasted with conventional trabeculectomy, MIGS demonstrates a favorable safety profile. Unfortunately, many patients cannot afford MIGS operations due to the high cost of most equipment. Purpose: The purpose of this research is to assess the effectiveness and safety of phacogoniotomy as well as the new phacoBANG MIGS procedures. This research has a prospective design. It ran from June 2022 to June 2024 at Benha University Hospitals' ophthalmology department. Patients whose cataracts were medically relevant and whose POAG was under medical management were included in the study. Each patient was randomly assigned to one of two groups: one that had phacoemulsification in conjunction with standard goniotomy using an MVR blade (group GON) and another that underwent phacoemulsification in conjunction with the innovative "Bent Ab interno Needle Goniectomy" method, which used a syringe that had been manually modified. There were two subgroups within each group: those with severe symptoms (GONs and BANGs) and those with mild symptoms (GONm and BANGm). Findings: Twenty-six eyes were part of the GON group and twenty-five eyes were part of the BANG group. For twelve months, patients were monitored. On average, the GON group used three different topical glaucoma drugs, resulting in an intraocular pressure (IOP) of 15±3 mmHg. Around one-third of patients had a decrease of at least 20% in intraocular pressure (IOP), and nearly eighty-nine percent needed one less medication.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/bjas.2024.325300.1512
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.